Recent posts

Our Guarantee

We promise to always go above and beyond for our customers.

Psyched Wellness Initiates a Clinical Sleep Study on Humans for a Structure/Function Claim for AME-1

Toronto, Ontario, September 21, 2021 – Psyched Wellness Ltd. (CSE:PSYC, OTCQB:PSYCF, FRANKFURT:5U9) (the “Company” or “Psyched”) a life sciences company focused on the production and distribution of artisanal functional and psychedelic mushrooms, is pleased to announce it has initiated first steps towards a clinical sleep study for a structure/function claim for the Company’s proprietary extract from Amanita Muscaria mushrooms, AME-1.

The study will be led by Psyched Wellness’s Board member and Head of the Company’s Scientific Committee, Professor David Nutt, a psychiatrist and the Edmond J. Safra Professor of psychopharmacology at the Imperial College London and the Chair of the Scientific Advisory Board for COMPASS Pathways.

The aim of the study is to carry out an assessment of a novel sleep enhancing food supplement for self-declared insomniacs based on both subjective and objective sleep measures, including residual effects.

Several conventional and over-the-counter sleep medications have residual effects and drowsiness. Psyched Wellness aims to develop new treatments that show a lack of residual hangover effects and increased alertness during the day.

Professor David Nutt, Board member and Head of the Company’s Scientific Committee said: “Psyched Wellness is researching the hugely important field of sleep and its disorders, and the Company’s proprietary AME-1 has the potential to assist with these. Positive results from this clinical study will allow the Company to write a claim on the future AME-1 supplement that the product can help with sleep while also improving daytime functioning.”

Professor David Nutt will lead this study, along with an experienced team, including:

  • Chris Alford PhD - Associate Professor of Psychology at the University of the West of England where he leads a group measuring the impact of drugs and other variables on cognitive processes especially sleep and driving. Dr. Alford is an advisor to the UK government on transport safety issues especially self-driving cars and advises on issues relating to cognitive impact of medicines on these.
  • Sue Wilson PhD - One of UK’s leading human EEG and physiological measurement experts for which she is much sought after by pharmaceutical companies doing phase 1 research using sleep as a measure of drugs effects. Dr. Wilson led the recent BAP consensus review of the treatment of sleep disorders.
  • Claire Durant PhD - After completing her PhD in EEG sleep recording at Bristol University, Dr. Durant joined DJN psychopharmacology team running human experimental studies on various GABAergic agents using sleep EEG and fMRI measures of effect.

“Completing the sleep study and obtaining a structure/function claim for AME-1 is a very significant milestone, not only for the Company but for everyone that suffers from insomnia and sleeping disorders," said David Shisel, COO of Psyched Wellness. “Developing a natural Amanita Muscaria Mushroom food supplement that has been clinically proven in human trials to help with sleeping disorders is very promising to the Company and to consumers world-wide.”